Compounds > olivacine
Page last updated: 2024-11-07

olivacine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Olivacine is a natural product isolated from the plant *Aspidosperma olivaceum*. It exhibits a variety of biological activities, including antitumor, antiviral, and antimicrobial properties. Olivacine is a potent inhibitor of DNA topoisomerase I, an enzyme essential for DNA replication and repair, which contributes to its antitumor activity. Its unique structure, characterized by a planar pentacyclic ring system, allows it to intercalate into DNA, disrupting its function. Olivacine's mechanism of action and its potential therapeutic applications have prompted extensive research efforts, including studies on its synthesis and modifications to enhance its efficacy and reduce its toxicity. Olivacine's biological properties and its intriguing structural features make it a valuable target for medicinal chemistry investigations.'

olivacine: alkaloid with antitumor & antileukemic activity isolated from Aspidosperma olivaceum; structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
AspidospermagenusA plant genus of the family APOCYNACEAE. It contains ellipticine.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]

Cross-References

ID SourceID
PubMed CID96364
CHEMBL ID306472
CHEBI ID7767
SCHEMBL ID613418
MeSH IDM0057872

Synonyms (25)

Synonym
olivacin
NSC70134 ,
6h-pyrido[4, 1,5-dimethyl-
nsc-70134
sj 2773
1,5-dimethyl-6h-pyrido(4,3-b)carbazole
inchi=1/c17h14n2/c1-10-12-7-8-18-11(2)14(12)9-15-13-5-3-4-6-16(13)19-17(10)15/h3-9,19h,1-2h
6h-pyrido[4,3-b]carbazole, 1,5-dimethyl-
1,5-dimethyl-6h-pyrido[4,3-b]carbazole
olivacine
C09230
484-49-1
CHEMBL306472
chebi:7767 ,
unii-5wsl5ll2c3
nsc 70134
6h-pyrido(4,3-b)carbazole, 1,5-dimethyl-
5wsl5ll2c3 ,
FT-0632199
olivacine [mi]
guatambuinine
SCHEMBL613418
DTXSID10197511
Q15425302
1,5-dimethyl-2h-pyrido[4,3-b]carbazole

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This report summarizes, in addition to pharmacokinetic data, the whole phase I clinical experience of S 16020 using three different infusion schedules."( Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.
Awada, A; Bleiberg, H; Brillanceau, MH; Calvo, F; De Valeriola, D; Dosquet, C; Eftekhary, P; Gerard, B; Giacchetti, S; Giroux, B; Lucas, C; Marty, M; Piccart, M; Poullain, MG; Soudon, J, 2002)		0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1152807Selectivity index, ratio of IC50 for mouse macrophages to IC50 for Plasmodium falciparum2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID1152806Cytotoxicity against mouse macrophages after 18 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID231710Ratio between brain tumor full panel [A] and sub panel [B]1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID1152800Antimalarial activity against Plasmodium berghei infected in mouse assessed as suppression of parasitemia at 50 mg/kg, po after 5 to 7 days2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID235001TGI correlation coefficient value of the compound1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID1152804Antiplasmodial activity against drug susceptible Plasmodium falciparum 3D7 NF54 isolate in human erythrocytes assessed as growth inhibition after 48 hrs by optical microscopy2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID78564Compound was evaluated for inhibitory activity against H69 human lung cancer cell line1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines.
AID143741Compound was evaluated for inhibitory activity against N 417 human lung cancer cell line1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines.
AID1152803Antiplasmodial activity against multi-drug resistant Plasmodium falciparum K1 in human erythrocytes assessed as growth inhibition after 48 hrs by optical microscopy2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID101087Antitumor activity against L1210 leukemia cells expressed as dose concentration that reduces number of cells by 50% after 48 hrs exposure to drug.1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and cytotoxic activity of hydroxylated derivatives of olivacine in relation with their biotransformation.
AID101215Antitumor efficiency against L1210 leukemia cells expressed as % increase in life span (ILS) 24 hrs after ip grafting (10e5 cells)1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and cytotoxic activity of hydroxylated derivatives of olivacine in relation with their biotransformation.
AID90125Concentration yielding an amount of cellular protein at the end of the incubation that is the same as at the beginning of the incubation in brain tumor sub panel1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
AID1152801Antimalarial activity against Plasmodium berghei infected in mouse assessed as suppression of parasitemia at 10 mg/kg, po after 5 to 7 days2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID78720Compound was evaluated for inhibitory activity against H 358 human lung cancer cell line1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines.
AID116694Cytotoxicity against L1210 leukemia cells administered through intraperitoneal route in mice1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and cytotoxic activity of hydroxylated derivatives of olivacine in relation with their biotransformation.
AID78722Compound was evaluated for inhibitory activity against H 460 human lung cancer cell line1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines.
AID90126Concentration yielding an amount of cellular protein at the end of the incubation that is the same as at the beginning of the incubation in full panel1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (15.38)18.7374
1990's6 (23.08)18.2507
2000's6 (23.08)29.6817
2010's5 (19.23)24.3611
2020's5 (19.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.95 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.45%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (93.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		1.9810amino-acid anion
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		4.570indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
carbazole
carbazole: structure in first source		3.1710carbazole
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		3.1710pyrrole;
secondary amine
elliptinium acetate
[no description available]		1.9810
elliptinium
elliptinium: synthetic ellipticine deriv; RN given refers to parent cpd; structure given in first source		2.3920carbazoles
chloroquine diphosphate
[no description available]		2.110
datelliptium chloride
detalliptinium: structure given in first source		1.9810
9-methoxyellipticine
9-methoxyellipticine: RN given refers to parent cpd		2.4220
cryptolepine
cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta. cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group.		7.0710indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound		anti-inflammatory agent;
antimalarial;
antineoplastic agent;
cysteine protease inhibitor;
plant metabolite
9-hydroxyellipticine
9-hydroxyellipticine: RN given refers to parent cpd. 9-hydroxyellipticine : A organic heterotetracyclic compound that is ellipticine in which the hydrogen at position 9 has been replaced by a hydroxy group.		2.6930organic heterotetracyclic compound;
organonitrogen heterocyclic compound		antineoplastic agent
murrayaquinone a
murrayaquinone A: a carbazole alkaloid from Murraya (Rutaceae); structure given in first source		3.1710
s 16020-2
S 16020-2: structure given in first source		9.341
9-methoxy-n(2)-methylellipticinium iodide
[no description available]		1.9810
quinine sulfate
[no description available]		2.110hydrate
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.6830
Cancer of Lung
[description not available]		02.730
Lung Neoplasms
Tumors or cancer of the LUNG.		02.730
Benign Neoplasms, Brain
[description not available]		01.9810
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		01.9810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.110
Benign Neoplasms
[description not available]		04.3741
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.3741
Acute Lymphoid Leukemia
[description not available]		02.2510
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		02.2510
Infections, Plasmodium
[description not available]		02.0710
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		07.0710
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		03.3911
Adenocarcinoma, Basal Cell
[description not available]		02.3920
Cancer of Colon
[description not available]		01.9810
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.3920
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9810
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		01.9910
Breast Cancer
[description not available]		01.9910
Carcinoma, Non-Small Cell Lung
[description not available]		01.9910
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.3820
B16 Melanoma
[description not available]		01.9910
Experimental Neoplasms
[description not available]		02.420
Diffuse Large B-Cell Lymphoma
[description not available]		01.9910
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9910
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		01.9910
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		01.9910
Mucositis, Oral
[description not available]		0210
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.		0210
American Trypanosomiasis
[description not available]		01.9510
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		01.9510